Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Cancers · 22.02.2024 · 16 (5) · 890
DOI: 10.3390/cancers16050890 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.02.2024. Verfasst von Anne Jacobsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular and Experimental Surgery, Translational Research Center, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlange…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, W. Lutzstiftung, Forschungsstiftung Medizin am Universitätsklinikum Erlangen.
Abstract (Originalsprache)
The vasculature is a key player and regulatory component in the multicellular microenvironment of solid tumors and, consequently, a therapeutic target. In colorectal carcinoma (CRC), antiangiogenic treatment was approved almost 20 years ago, but there are still no valid predictors of response. In addition, treatment resistance has become a problem. Vascular heterogeneity and plasticity due to species-, organ-, and milieu-dependent phenotypic and functional differences of blood vascular cells reduced the hope of being able to apply a standard approach of antiangiogenic therapy to all patients. In addition, the pathological vasculature in CRC is characterized by heterogeneous perfusion, impaired barrier function, immunosuppressive endothelial cell anergy, and metabolic competition-induced microenvironmental stress. Only recently, angiocrine proteins have been identified that are specifically released from vascular cells and can regulate tumor initiation and progression in an autocrine and paracrine manner. In this review, we summarize the history and current strategies for applying antiangiogenic treatment and discuss the associated challenges and opportunities, including normalizing the tumor vasculature, modulating milieu-dependent vascular heterogeneity, and targeting functions of angiocrine proteins. These new strategies could open perspectives for future vascular-targeted and patient-tailored therapy selection in CRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Molecular and Experimental Surgery, Translational Research Center, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Kussmaulallee 12, D-91054 Erlangen, Germany.
- Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), D-91054 Erlangen, Germany.
- Department of General and Visceral Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
- Department of Medicine 1-Gastroenterology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), D-91054 Erlangen, Germany.
ORCID-Profile: Elisabeth Naschberger
Förderung
- Deutsche Forschungsgemeinschaft
- W. Lutzstiftung
- Forschungsstiftung Medizin am Universitätsklinikum Erlangen
- German Research Foundation (DFG) FOR 2438, subproject 2
- DFG SFB/TRR 241, subproject A06
- DFG STU 238/10-1
- DFG TRR 305, subproject B08
- DFG-NOTICE program
Zitieren
APA
Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024). Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. Cancers, 16(5), 890. https://doi.org/10.3390/cancers16050890
Vancouver
Jacobsen A, Siebler J, Grützmann R, Stürzl M, Naschberger E. Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives. Cancers. 2024;16(5):890. doi:10.3390/cancers16050890
BibTeX
@article{Jacobsen2024,
author = {Jacobsen, Anne and Siebler, Jürgen and Grützmann, Robert and Stürzl, Michael and Naschberger, Elisabeth},
title = {Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives},
journal = {Cancers},
year = {2024},
volume = {16},
number = {5},
pages = {890},
doi = {10.3390/cancers16050890}
}
EUVIMED